Form 8-K - Current report:
SEC Accession No. 0001628280-25-031455
Filing Date
2025-06-16
Accepted
2025-06-16 07:48:32
Documents
17
Period of Report
2025-06-13
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aqst-20250613.htm   iXBRL 8-K 28194
2 EX-99.1 prndaacceptancedraft6-13.htm EX-99.1 14087
6 prndaacceptancedraft6-13001.jpg GRAPHIC 229018
7 prndaacceptancedraft6-13002.jpg GRAPHIC 248380
8 prndaacceptancedraft6-13003.jpg GRAPHIC 291797
9 prndaacceptancedraft6-13004.jpg GRAPHIC 217719
  Complete submission text file 0001628280-25-031455.txt   1523369

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aqst-20250613.xsd EX-101.SCH 1776
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aqst-20250613_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aqst-20250613_pre.xml EX-101.PRE 12504
19 EXTRACTED XBRL INSTANCE DOCUMENT aqst-20250613_htm.xml XML 2719
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38599 | Film No.: 251048552
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)